Altrinsic Global Advisors LLC Voyager Therapeutics, Inc. Transaction History

Altrinsic Global Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$10.01 - $13.75 $400,400 - $550,000	-40,000 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$8.05 - $14.21 $80,500 - $142,100	-10,000 Reduced 20.0%	40,000 $505,000
Q1 2020 May 14, 2020	BUY	$6.8 - $14.66 $340,000 - $733,000	50,000 New	50,000 $458,000
Q3 2019 Nov 14, 2019	SELL	$16.31 - $28.29 $815,499 - $1.41 Million	-50,000 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$19.18 - $27.88 $2.68 Million - $3.9 Million	-139,927 Reduced 73.67%	50,000 $1.36 Million
Q4 2018 Feb 14, 2019	BUY	$8.59 - $18.05 $85,900 - $180,500	10,000 Added 5.56%	189,927 $1.79 Million
Q3 2018 Nov 14, 2018	BUY	$17.11 - $21.74 $85,550 - $108,699	5,000 Added 2.86%	179,927 $3.4 Million
Q1 2018 May 14, 2018	SELL	$16.16 - $31.31 $1.45 Million - $2.82 Million	-90,000 Reduced 33.97%	174,927 $3.29 Million
Q4 2017 Feb 13, 2018	BUY	$12.26 - $25.88 $1.23 Million - $2.59 Million	100,000 Added 60.63%	264,927 $4.4 Million
Q3 2017 Nov 14, 2017	BUY	$8.37 - $20.59 $1.38 Million - $3.4 Million	164,927	164,927 $3.4 Million

128

36.7M

48K

36.2K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $226M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Altrinsic Global Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Altrinsic Global Advisors LLC with notifications on news.